New Aspects on Neurological Manifestations in Fabry Diseases, Drug Management and Comprehensive Review
Author(s): Lourdes de Fátima Ibañez Valdés, Humberto Foyaca Sibat*
Abstract
Introduction: We searched the medical literature, following the guidelines outlined in the PRISMA statement. From 01st, January 1982 to 31st, July 2025, the authors searched the scientific databases, Scopus, Embassy, Medline, and PubMed Central using the following searches: “Fabry disease” OR “agalsidase alfa” OR “agalsidase beta” OR “lysosomal storage disease” OR “enzyme replacement therapy”, OR “migalastat” OR “α?galactosidase A” OR “globotriaosylceramide” OR “globotriaosylsphingosine”.
Results: After screening the full?text articles for relevance, n=2172 articles were identified through database searching. Included for the first screen n=1193. Records after duplicates removed n=923, record included for full?test review n=270. Excluded by full?test review n=101studies. Include publications for initial searches n=169. Additional reports after search es identified references (covering 171 studies) n=182. Identified publication with new proposal of pathogenesis included in final review and meta?analysis n=0. No article proposing a new hypothesis for pathogenesis of FD responding to drug therapy was found when we searched. Therefore, meta?analysis was not performed.
Conclusions: To the best of our knowledge, this is the first study proposing an update drug therapy program to control neurological manifestations of FD.